Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 11/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085483 | 0.82 | ALDH1A1 (0.45) | ADAMTS5MMP2MMP13ADAMTS4MMP3 | |
| SCHEMBL12378675 | 0.79 | ALDH1A1 (0.42) | ADAMTS5MMP2MMP13ADAMTS4MMP3 | |
| SCHEMBL12378820 | 0.77 | ADAM17 (0.51) | ADAMTS5MMP2MMP13MMP3ALDH1A1 | |
| SCHEMBL29372256 | 0.74 | ADAMTS7 (0.52) | ADAMTS5MMP2MMP13ADAMTS4MMP3 | |
| SCHEMBL12378835 | 0.73 | SMN1; SMN2 (0.68) | ADAMTS5MMP2MMP13FPR2SMN1; SMN2 | |
| SCHEMBL12378824 | 0.72 | SMN1; SMN2 (0.48) | ADAMTS5MMP2MMP13ADAMTS4MMP3 | |
| SCHEMBL12378821 | 0.72 | ADAMTS5 (0.43) | ADAMTS5MMP2MMP13FPR2ADAMTS4 | |
| SCHEMBL12378832 | 0.71 | PLCG1 (0.44) | ADAMTS5MMP2MMP13MMP12SMN1; SMN2 | |
| SCHEMBL12378830 | 0.70 | ADAMTS5 (0.42) | ADAMTS5MMP2MMP13FPR2ADAMTS4 | |
| SCHEMBL204119 | 0.66 | LMNA (0.51) | ADAMTS5MMP2MMP13ALDH1A1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | ADAMTS5 3194/4885MMP2 1337/4885MMP13 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.